PXD101

DRUG4 trials

Sponsors

Valerio Therapeutics

Conditions

Acute Myeloid LeukemiaDose Escalation: Solid TumorsMTD: Soft Tissue SarcomasMultiple Myeloma

Phase 1

A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue Sarcomas

CompletedNCT00878800

Valerio TherapeuticsDose Escalation: Solid Tumors, MTD: Soft Tissue Sarcomas

Start: 2006-12-31End: 2012-10-31Updated: 2015-07-28

Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive Therapy

CompletedNCT00878722

Valerio TherapeuticsAcute Myeloid Leukemia

Start: 2007-08-31End: 2012-04-30Updated: 2015-07-28

Phase 2

Clinical Trial of PXD101 in Patients With Advanced Multiple Myeloma

CompletedNCT00131261

Valerio TherapeuticsMultiple Myeloma

Start: 2005-01-31End: 2007-06-30Updated: 2015-07-08

A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

TerminatedNCT00431340

Valerio TherapeuticsMultiple Myeloma

Start: 2007-03-31End: 2007-06-30Updated: 2015-07-08

Related Papers

A phase I/II clinical trial of belinostat (PXD101) in combination with doxorubicin in patients with soft tissue sarcomas (STS).

Journal of Clinical Oncology2015-05-204 citations